Stokes & Hubbell Capital Management LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% in the fourth quarter, HoldingsChannel reports. The firm owned 111,961 shares of the company’s stock after selling 534 shares during the period. Johnson & Johnson accounts for 3.8% of Stokes & Hubbell Capital Management LLC’s investment portfolio, making the stock its 4th largest holding. Stokes & Hubbell Capital Management LLC’s holdings in Johnson & Johnson were worth $15,643,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Harding Loevner LP acquired a new position in shares of Johnson & Johnson during the 2nd quarter valued at about $106,000. IHT Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 46.4% during the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after acquiring an additional 3,467 shares during the last quarter. Mountain Capital Investment Advisors Inc acquired a new position in shares of Johnson & Johnson during the 2nd quarter valued at about $124,000. Lenox Wealth Management Inc. increased its holdings in shares of Johnson & Johnson by 1.7% during the 2nd quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock valued at $193,000 after acquiring an additional 24 shares during the last quarter. Finally, Intercontinental Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter valued at about $200,000. 67.23% of the stock is owned by institutional investors.
In other news, VP Paulus Stoffels sold 155,342 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the sale, the vice president now owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.22% of the stock is currently owned by company insiders.
JNJ opened at $128.10 on Friday. Johnson & Johnson has a 12-month low of $120.95 and a 12-month high of $148.32. The company has a market capitalization of $349,877.28, a price-to-earnings ratio of 17.55, a price-to-earnings-growth ratio of 2.07 and a beta of 0.74. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.51.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The company had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. During the same quarter last year, the firm earned $1.58 EPS. Johnson & Johnson’s revenue for the quarter was up 11.5% compared to the same quarter last year. research analysts expect that Johnson & Johnson will post 8.11 EPS for the current fiscal year.
WARNING: This article was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3337751/stokes-hubbell-capital-management-llc-cuts-stake-in-johnson-johnson-jnj.html.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.